SG&A Spending Patterns: A Tale of Two Biotechs

In the dynamic world of biotechnology, understanding financial trends is crucial. Over the past decade, Genmab A/S and Novavax, Inc. have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Genmab's SG&A expenses surged by an astounding 4,000%, reflecting its aggressive expansion and strategic investments. In contrast, Novavax's expenses grew by approximately 2,300%, indicating a more measured approach.

A Decade of Growth

Genmab's spending peaked in 2023, with expenses reaching nearly 3.3 billion, a testament to its robust growth strategy. Meanwhile, Novavax's expenses, though significantly lower, also saw a notable increase, peaking at around 469 million in 2022. This divergence highlights the varied strategies these companies employ to navigate the competitive biotech landscape.

Understanding these patterns offers valuable insights into the operational priorities and market positioning of these industry players.